Clovis Oncology Profile

USD 1.19  2.05%

Sale by Gillian IversRead of 3000 shares of Clovis Oncology

Clovis Oncology Inc insider trading alert for sale of common stock by Gillian IversRead, Executive Vice President of Technical Operations and Chief Regulatory Officer, on February 16, 2018. This event was filed by Clovis Oncology Inc with SEC on 2018-02-16. Statement of changes in beneficial ownership - SEC Form 4. Gillian IversRead is currently serves as executive vice president - technical operations, chief regulatory officer of Clovis Oncology Inc [view details]   

Clovis Oncology Summary

Clovis Oncology Inc (CLVS) is traded on NASDAQ in USA. It is located in COLORADO, U.S.A and employs 360 people. Clovis Oncology is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Mid-Cap' category with current market capitalization of 2.97 B. Clovis Oncology Inc conducts business under Healthcare sector and is part of Pharmaceutical Products industry. This company has 50.57 M outstanding shares of which 6.95 M shares are currently shorted by private and institutional investors with about 5.48 trading days to cover. Clovis Oncology currently holds about 563.73 M in cash with (260.9 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 11.15.
Check Clovis Oncology Probability Of Bankruptcy

Ownership Allocation (%)

Top Holders

Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
Vanguard Group IncCommon Shares3.9 M266.7 M
Blackrock IncCommon Shares3.7 M253.4 M
Linden Advisors LpDebt84.8 M114.7 M
Susquehanna International Group LlpCall Options845.6 K57.5 M
View Clovis Oncology Diagnostics

Selected Clovis Oncology Inc Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Key Fundamentals

Clovis Oncology Against Markets

Risk Adjusted
Performance Score (0 to 100)
Chance of
Financial Distress (0 to 100%)
< 13% 
Equity ratings for Clovis Oncology Inc are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Clovis Oncology, Inc. was founded in 2009 and is headquartered in Boulder, Colorado. Clovis Oncology operates under Biotechnology classification in USA and traded on NASDAQ exchange. It employs 360 people. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
NameClovis Oncology Inc
President CEO, DirectorPatrick MahaffyView All
Analyst Consensus
Piotroski F Score
Macroaxis Advice
InstrumentUSA Stock View All
RegionNorth America
Business Address5500 Flatiron Parkway
CIK Number01466301.0
IndustryPharmaceutical Products
Contact Number303 625 5000
CurrencyUSD - US Dollar


Clovis Oncology Analyst Recommendations
Target PriceAdvice# of Analysts
Clovis Oncology Inc current and past analyst recommendations published by number of research institutions as well as average analyst consensus
Clovis Oncology Analyst Advice  


Explore Investment Opportunities
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked.
Explore Investing Ideas  


Clovis Oncology Earnings Estimates
EPSEstimate Date
Quarterly Estimate-1.43May 4, 2017
Clovis Oncology Inc normalized analysts earnings estimates for actual as well as projected forward EPS values taken as an average expert opinion over time
Earnings Estimate  


Clovis Oncology Corporate Directors
James Blair Independent Director
Thorlef Spickschen Independent Director, Ph.D
Brian Atwood Independent Director, MBA